Greenwood Capital Associates LLC Raises Position in Gilead Sciences, Inc. (GILD)

Greenwood Capital Associates LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,170 shares of the biopharmaceutical company’s stock after purchasing an additional 1,126 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Gilead Sciences were worth $1,777,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Abner Herrman & Brock LLC lifted its stake in Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 50 shares during the last quarter. Blue Fin Capital Inc. lifted its stake in Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 55 shares during the last quarter. Searle & CO. lifted its stake in Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 80 shares during the last quarter. Alpha Windward LLC lifted its stake in Gilead Sciences by 2.4% in the first quarter. Alpha Windward LLC now owns 3,921 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 92 shares during the last quarter. Finally, TFS Capital LLC lifted its stake in Gilead Sciences by 1.4% in the first quarter. TFS Capital LLC now owns 6,791 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 97 shares during the last quarter. 74.05% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on the company. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, August 31st. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price objective on the stock. in a research note on Monday, August 28th. Cowen and Company restated an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 5th. Finally, Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research note on Wednesday, September 6th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $83.79.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-shares-bought-by-greenwood-capital-associates-llc/1566101.html.

Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.09% during midday trading on Friday, reaching $82.36. The company had a trading volume of 12,401,948 shares. The company has a market cap of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19. The company’s 50-day moving average is $77.16 and its 200 day moving average is $70.20. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue was down 8.2% compared to the same quarter last year. During the same period last year, the company earned $3.08 earnings per share. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. Gilead Sciences’s dividend payout ratio is 22.58%.

In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.